EPO and chronic kidney disease: In patients, EPO showed beneficial effects on the 29-day survival rate, different from the two previous randomized trials, probably due to the distinctly larger CKD population in our study; stage 3–5 CKD here vs. stage 1–2 CKD in the previous publications [56,57].